PORTLAND, Ore., May 8, 2008 (PRIME NEWSWIRE) -- Znomics, Inc. (OTCBB:ZNOM), a pioneer in the development of the zebrafish as a vertebrate genetic platform to accelerate drug discovery, announced today a collaborative research program with the University of Utah and its Huntsman Cancer Institute (HCI) to develop pre-clinical compounds for the treatment of T-cell leukemia, autoimmune diseases, inflammation and complications related to organ transplantation.
